The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics?

Neuroscience and Biobehavioral Reviews

Volumn 23, Issue 6, 1999, Pages 851-862

  Wadenberg, Marie Louise G ^a   Hicks, Paul B ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Antipsychotic drugs; Brain neurotransmitter receptors; Conditioned avoidance response; Nucleus accumbens(shell); Rat

Indexed keywords

AMPHETAMINE; ANALGESIC AGENT; ATROPINE; BUSPIRONE; BUTYROPHENONE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR; FLESINOXAN; GLUTAMATE RECEPTOR; HOMOVANILLIC ACID; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; OPIATE ANTAGONIST; PHENCYCLIDINE; PHENOTHIAZINE DERIVATIVE; RACLOPRIDE; RECEPTOR SUBTYPE; RISPERIDONE; RITANSERIN; SCOPOLAMINE; SEROTONIN RECEPTOR; SERTINDOLE; UNINDEXED DRUG;

AVOIDANCE BEHAVIOR; BINDING SITE; DRUG ACTIVITY; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA;

EID: 0032888408     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(99)00037-8     Document Type: Article

References (122)

1. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats. Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol. 51:1982;321-329.
2. Cook L., Morris R.W., Mattis P.A. Neuropharmacological and behavioral effects of chlorpromazine (thorazine hydrochloride). J Pharmacol Exp Ther. 113:1955;11-12.
3. Cook L., Weidley E. Behavioral effects of some psychopharmacological agents. Ann NY Acad Sci. 66:1957;740-752.
4. Courvoisier S., Fournel J., Ducrot R., Kolsky M., Koetschet P. Propriétés pharmacodynamiques du chlorhydrate de chloro3 (diméthylamino3′ propyl)10 phénothiazine (4560 R.P.). Arch Int Pharmacodyn. 92:1953;305-361.
5. Courvoisier S. Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J Clin Exp Psychopathol Quart Rev Psychiat Neurol. 17:1956;25-37.
6. Davidson A.B., Weidley E. Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci. 18:1976;1279-1284.
7. Ponsluns D. An analysis of chlorpromazine-induced suppression of the avoidance response. Psychopharmacologia. 3:1962;361-373.
8. Verhave T., Owen J.E. Jr., Robbins E.B. Effects of chlorpromazine and secobarbital on avoidance and escape behavior. Arch Int Pharmacodyn. 116:1958;45-53.
9. Wadenberg M.L., Ahlenius S., Svensson T.H. Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology. 110:1993;273-279.
10. Essman W.D., Lucki I. Animal behavioral approaches. Fraser A., Molinoff P., Winokur A. Biological bases of brain function and disease. 1994;241-260 Raven Press, New York.
11. Kuribara H., Tadokoro S. Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav. 14:1981;181-192.
12. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
13. Heimer L., Alheid G.F., Zahm D.S. Basal forebrain organization: an anatomical framework for motor aspects of drive and motivation. Kalivas P.W., Barnes C.D. Limbic motor circuits and neuropsychiatry. 1993;1-43 CRC Press, Boca Raton, FL.
14. Heimer L., Alheid G.F., de Olmos J.S., Groenewegen H.J., Haber S.N., Harlan R.E., Zahm D.S. The accumbens: beyond the core-shell dichotomy. J Neuropsychiat. 9:1997;354-381.
15. Hicks P.B., Browning J., Barwick S., Jones D., Wadenberg M.-L., Richter J.T., Young K.A. M100,907 acts at both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. Schizophr Res. 36:1999;115.
16. Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: functional interface between the limbic and the motor system. Progr Neurobiol. 14:1980;69-97.
17. Wadenberg M.-L., Ericson E., Magnusson O., Ahlenius S. Suppression of conditioned avoidance behavior by the local application of (-)sulpiride into the ventral, but not the dorsal, striatum of the rat. Biol Psychiat. 28:1990;297-307.
18. Carlsson A., Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
19. Randrup A., Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour. Psychopharmacologia. 7:1965;416-422.
20. Randrup A., Munkvad I. Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomole Psychiat. 1:1972;2.
21. Seiden L.S., Carlsson A. Temporary and partial antagonism by LDOPA of reserpine-induced suppression of a conditioned avoidance response. Psychopharmacologia. 4:1963;418-423.
22. Davies J.A., Jackson B., Redfern P.H. The effect of antiparkinsonian drugs on haloperidolinduced inhibition of the conditioned avoidance response in rats. Neuropharmacology. 12:1973;735-740.
23. Koob G.F., Simon H., Herman J.P., LeMoal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems. Brain Res. 303:1984;319-329.
24. Ahlenius S. An analysis of behavioral effects produced by drug-induced change of dopaminergic neurotransmission in the brain. Scand J Psychol. 20:1979;59-64.
25. Wadenberg M.-L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm. 83:1991;43-53.
26. Blackburn J.R., Phillips A.G. Enhancement of freezing behaviour by metoclopramide: implications for neuroleptic-induced avoidance deficits. Pharmacol Biochem Behav. 35:1990;685-691.
27. Hunziker F., Fischer E., Schmutz J. 11-Amino-5H-dibenzo(b,e)-1,4-diazepine-10. Mitteilungen über siebengliedrige Heterocyclen. Helv Chim Acta. 50:1967;1588.
28. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
29. Snyder S., Greenberg D., Yamamura H.I. Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal side effects. J Psychiat Res. 11:1974;91-95.
30. Janssen P.A.J., Niemegeers C., Awouters F., Schellekens K.H.L., Megens A.A.H.P., Meert T.F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther. 244:1988;685-693.
31. Seiden L.S., Dykstra L.A. Psychopharmacology: a biochemical and behavioral approach. 1977;Van Nostrand Reinhold, New York.
32. Li C.C. 1964;McGraw-Hill, New York. pp. 207-226.
33. Wadenberg M.-L., Young K.A., Trompler R.A., Zavodny R.A., Richter T.J., Hicks P.B. A novel computer controlled conditioned avoidance apparatus for rats. J Pharmacol Toxicol Meth. 38:1998;211-215.
34. Salmi P., Samuelsson J., Ahlenius S. A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Meth. 32:1994;155-159.
35. Warner L.H. The association span of the white rat. J Genet Psychol. 41:1932;57-90.
36. Heise G.A., Boff E. Continuous avoidance as a baseline for measuring behavioral effects of drugs. Psychopharmacologia. 3:1962;264-282.
37. Sidman M. Avoidance conditioning with brief shock and no exteroceptive warning signal. Science. 118:1953;157-158.
38. Latz A., Bain G.T., Kornetsky C. Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia. 14:1969;23-32.
39. Low L.A., Eliasson M., Kornetsky C. Effect of chlorpromazine on avoidance acquisition as a function of CS-US interval length. Psychopharmacologia. 10:1966;148-154.
40. Ahlenius S. Inhibition of catecholamine synthesis and conditioned avoidance acquisition. Pharmacol Biochem Behav. 1:1973;347-350.
41. Fibiger H.C., Zis A.P., Phillips A.G. Haloperidol-induced disruption of conditioned avoidance response: attenuation by prior training or by anticholinergic drugs. Eur J Pharmacol. 30:1975;309-314.
42. Barrett R.J., Leith N.J., Ray O.S. Permanent facilitation of avoidance behavior by d-amphetamine and scopolamine. Psychopharmacologia. 25:1972;321-331.
43. Rech R.H. Amphetamine effects on poor performance of rats in a shuttlebox. Psychopharmacologia. 9:1965;110-117.
44. Coyle J.T. Jr., Wender P., Lipsky A. Avoidance conditioning in different strains of rats: neurochemical correlates. Psychopharmacologia. 31:1973;25-34.
45. Plech A., Herman Z.S., Drybanski A. Rate of learning of the conditioned avoidance reflex in rats with various exploratory activity. Arch Immunol Ther Exp. 23:1975;445-448.
46. Büch T.O., DeliniStula A., Eigenmann R., Levin P.H. Pharmacologische Untersuchungen zur Wirkung von Neuroleptica am Tier nach einmaliger und wiederholter Applikation. Arzneimittel-Forschung. 18:1968;1491-1495.
47. Möller Nielsen I., Fjalland B., Pedersen V., Nymark M. Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia. 34:1974;95-104.
48. Sanger D.J. The effects of clozapine on shuttlebox avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav. 23:1984;231-236.
49. Fowler S.C., Ford K.E., Gramling S.E., Nail G.L. Acute and subchronic effects of neuroleptics on quantitative measures of discriminative motor control in rats. Psychopharmacology. 84:1984;368-373.
50. Bignami G. Selection for high rates and low rates of avoidance conditioning in the rat. Animal Behav. 13:1965;2-3.
51. Hansson L.C.F. The disruption of conditioned avoidance response following selective depletion of brain catecholamines. Psychopharmacologia. 8:1965;100-110.
52. Knoll J., Knoll B., Niklya I. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. Life Sci. 58:1996;945-952.
53. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
54. Norman R.W., Malla A.K. Stressful life events in schizophrenia: concepts and methodology. Br J Psychiat. 162:1993;166-174.
55. Friedhoff A.J., Carr K.D., Uysal S., Schweitzer J. Repeated inescapable stress produces a neurolepticlike effect on the conditioned avoidance response. Neuropsychopharmacology. 13:1995;129-138.
56. Estes W.K., Skinner B.F. Some quantitative properties of anxiety. J Exp Psychol. 29:1941;390-400.
57. Inoue T., Tsuchiya K., Koyama T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav. 55:1996;195-201.
58. Weiner I., Feldon J. Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology. 91:1987;248-253.
59. Verhave T., Owen J.E. Jr., Robbins E.B. Effects of secobarbital and pentobarbital on escape and avoidance behavior. Psychol Rep. 3:1957;421-428.
60. Verhave T., Owen J.E. Jr., Robbins E.B. The effect of morphine sulfate on avoidance and escape behavior. J Pharm Exp. 125:1959;248-251.
61. Izquierdo I. Relations between orienting, pseudoconditioned and conditioned responses in the shuttle-box - a pharmacological analysis by means of LSD and dibenamine. Behav Biol. 15:1975;193-205.
62. Torre M., Torre E., Bogetto F. The relation between cerebral serotonin levels and conditioned behaviour in the rat following the administration of LSD-25 and UML. Psychopharmacologia. 41:1975;245-247.
63. Creese I., Burt D.R., Snyder S.H. The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci. 17:1975;1715-1720.
64. Titeler M., Lyon R., Glennon R. Radioligand binding evidence implicates the brain 5-HT-2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
65. Browning J.L., Wadenberg M.-L., Young K.A., Richter J., Hicks P.B. The role of serotonergic antagonism in the suppression of conditioned avoidance by clozapine in rats. Soc Neurosci. 24:1998;1741.
66. Clarke R., Samuel G.K. Drug effects on a discrete conditioned avoidance response in dogs, rhesus monkeys and rats. Psychopharmacologia. 14:1969;106-114.
67. Reynoldson J.A., Bentley G.A. The effect of narcotic analgesics and their antagonists on conditioned avoidance in the rat. Clin Exp Pharmacol Physiol. 1:1974;503-518.
68. Besson A., Privat A.M., Eschalier A., Fialip J. Reversal of learned helplessness by morphine in rats: involvement of a dopamine mediation. Pharmacol Biochem Behav. 60:1998;519-525.
69. Desole M.S., Esposito G., Fresu L., Migheli R., Enrico P., Mura M.A., De Natale G., Miele E., Miele M. Effects of morphine treatment and withdrawal on striatal and limbic monoaminergic activity and ascorbic acid oxidation in the rat. Brain Res. 723:1996;154-161.
70. Enrico P., Mura M.A., Esposito G., Serra P., Migheli R., De Natale G., Desole M.S., Miele E., Miele M. Effect of naloxone on morphine-induced changes in striatal dopamine metabolism and glutamate, ascorbic acid and uric acid release in freely moving rats. Brain Res. 797:1998;94-102.
71. Lichtigfield F.J., Gillman M.A. Role of dopamine mesolimbic system in opioid action of psychotropic analgesic nitrous oxide in alcohol and drug withdrawal. Clin Neuropharmacol. 19:1996;246-251.
72. Goldberg M.E., Johnson H.E., Knaak J.B., Smyth H.F. Psychopharmacological effects of reversible cholinesterase inhibition induced by N-methyl 3-isopropyl phenyl carbamate (compound 10 854). J Pharm Exp. 141:1963;244-252.
73. Goldberg M.E., Johnson H.E., Knaak J.B. Inhibition of discrete avoidance behavior by three anticholinesterase agents. Psychopharmacologia. 7:1965;72-76.
74. Stone G.C. Effects of drugs on nondiscriminated avoidance behavior. Psychopharmacologia. 6:1964;245-255.
75. Perry K.W., Bymaster F.P., Shannon H.E., Rasmussen K., DeLapp N.W., Zhang W., Ward J.S., Calligaro D.O., Fink-Jensen A., Sheardown M., Jeppesen L., Sauerberg P. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res. 36:1999;117-118.
76. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., Delapp N.W., Whitesitt C., Ward J.S., Thompsen C., Rasmussen T., Sheardown M.J., Jeppesen L., Sauerberg P., Bymaster F.P. The selective muscarinic agonist BuTAC inhibits d-amphetamine-induced Fos protein immunoreactivity in limbic areas of the rat brain. Schizophrenia Res. 36:1999;308.
77. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiat. 45:1988;789-796.
78. Meltzer H.Y. Atypical antipsychotic drugs. Bloom F.E., Kupfer D.J. Psychopharmacology: the fourth generation of progress. 1995;1277-1286 Raven Press, New York.
79. 4. Neuropsychopharmacology. 7:1992;261-284.
80. 4 receptors. Neuropsychopharmacology. 16:1997;93-122.
81. Cohen B.M., Lipinski J.F. In vivo potencies of antipsychotic drugs in blocking alpha-1 and dopamine D2 receptors: implications for drug mechanism of action. Life Sci. 39:1986;2571-2580.
82. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiat. 137:1980;1518-1522.
83. Mason S.L., Reynolds G.P. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol. 221:1992;397-398.
84. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631:1993;191-202.
85. 2 receptor blocking agent ritanserin in the rat. Eur Neuropsychopharmacol. 6:1996;305-310.
86. 2A receptor antagonist MDL 100,907. Biol Psychiat. 44:1998;508-515.
87. Wadenberg M.-L., Richter T.J., Hicks P.B. Further evidence for a role of the 5-HT2A receptor in the mediation of antipsychotic-like activity in the rat. Schizophr Res. 1997;. abstract.
88. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathé J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedeberg's Arch Pharmacol. 352:1995;374-385.
89. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from pet imaging. Mol Psychiat. 3:1998;135-140.
90. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther. 262:1992;545-551.
91. Fagerquist M.V., Wadenberg M.-L., Svensson T.H. Effects of sertindole on conditioned avoidance response in rats. Scand Soc Psychopharmacol. 1998;. abstract.
92. Prinssen E.P.M., Kleven M.S., Koek W. Effects of dopamine antagonists in a two-way active avoidance procedure in rats - interactions with 8-OH-DPAT, ritanserin and prazosin. Psychopharmacology. 128:1996;191-197.
93. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
94. 1A receptor agonist, potentiated S(-)sulpiride-induced DA release in rat medial prefrontal cortex. Soc Neurosci. 23:1997;401.
95. Medrano J., Padierna J.A. Disappearance of psychosis after buspirone treatment. Am J Psychiat. 153:1996;293.
96. Goff D.C., Midha K.K., Brotman A.W., McCormick S., Waites M., Amico E.T. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol. 11:1991;193-197.
97. Piercey M.F., Smith M.W., Lum-Ragan J.T. Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther. 268:1994;1297-1303.
98. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M. S 16924 ((R)-2-[1-[2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4- fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther. 286:1998;1356-1373.
99. 2 antagonists: potential antipsychotics. Soc Neurosci Abstr. 22:1996;1325.
100. Norman M.H., Rigdon G.C., Hall W.R., Navas F. III. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1A agonists as neuroleptic agents. J Med Chem. 39:1996;1172-1188.
101. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schultz D.W., Lebel L.A., McLean S., Guanowsky V., Howard H.R., Lowe J.A., et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 275:1995;101-113.
102. 4 receptors elevated in schizophrenia. Nature. 365:1993;441-445.
103. Bristow L.J., Collinson N., Cook G.P., Curtis N., Freedman S.B., Kulagowski J.J., Leeson P.D., Patel S., Ragan C.I., Ridgill M., Saywell K.L., Tricklebank M.D. L-745,870, a suntype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther. 283:1997;1256-1263.
104. Kramer M.S., Last B., Getson A., Reines S.A., Silva J.A., Wirshing W., Conley R.A.E., Cheng H.Y., Chavezeng C. The effects of a selective D-4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiat. 54:1997;567-572.
105. Mansbach R.S., Brooks E.W., Sanner M.A., Zorn S.H. Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology. 135:1998;194-200.
106. Tang A.H., Franklin S.R., Himes C.S., Smith M.W., Tenbrink R.E. PNU-96415E: a potential antipsychotic agent with clozapine-like pharmacological properties. J Pharmacol Exp Ther. 281:1997;440-447.
107. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
108. Moghaddam B. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiat. 18:1994;859-870.
109. Ericson E., Ahlenius S. Phencyclidine-induced disruption of an aversely motivated two-choice successive discrimination in the rat. Psychopharmacology. 102:1990;171-174.
110. Mele A., Battaglia M., Sansone M. Reversal of chlorpromazine-induced avoidance depression by the N-methyl-d-aspartate antagonist dizocilpine in mice. J Pharm Pharmacol. 46:1994;390-392.
111. Mathé J.M., Nomikos G.G., Schilström B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 1997.
112. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-d-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J Pharmacol Exp Ther. 265:1993;1001-1010.
113. Svensson T.H., Mathé J.M., Fagerquist M.V., Wadenberg M.-L. An antipsychotic effect of AMPA receptor antagonists is indicated by suppression of conditioned avoidance response in the rat. Schizophr Res. 36:1999;316.
114. Fantin G., Bottechia D. Effect of nucleus accumbens destruction in rat. Experientia. 40:1984;573-575.
115. Fibiger H.C., Phillips A.G., Zis A.P. Deficits in instrumental responding after 6-hydroxydopamine lesions of the nigro-striatal dopaminergic projection. Pharmacol Biochem Behav. 2:1974;87-96.
116. Kostowski W., Plaznik A., Pucilowski O. Effect of chronic clonidine treatment and lesion of the locus coeruleus on the conditioned avoidance behavior in rats. Polish J Pharmacol Pharm. 32:1980;305-312.
117. Turski L., Czuczwar S.J., Turski W., Kleinrok Z. Shuttle behavior in rats after lesion of hippocampal pyramidal cells with kainic acid. Meth Findings Exp Clin Pharmacol. 3:1981;361-366.
118. Bardgett M.E., Jacobs P.S., Jackson J.L., Csernansky J.G. Kainic acid lesions enhance locomotor responses to novelty, saline, amphetamine, and MK-801. Behav Brain Res. 84:1997;1-2. also pp. 47-55.
119. Kostowski W., Plaznik A. Decreased disrupting effect of neuroleptics on conditioned avoidance in rats with lesions in the mid-brain raphe nuclei. Physiol Behav. 29:1982;621-626.
120. Jackson D.M., Ahlenius S., Andén N.E., Engel J. Antagonism by locally applied dopamine into the nucleus accumbens or the corpus striatum of alpha-methyltyrosine-induced disruption of conditioned avoidance behaviour. J Neural Transm. 41:1977;231-239.
121. Ericson E., Svensson T.H., Ahlenius S. Loss of discriminative avoidance behavior by local application of kyneurenic acid into the nucleus accumbens of the rat. Pharmacol Biochem Behav. 37:1990;843-845.
122. Gross H., Langer E. Das Wirkungsprofile eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepinegruppe. Wien Med Wochenschr. 116:1966;814-816.